Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHUKRA PHARMA vs IPCA LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHUKRA PHARMA IPCA LABS SHUKRA PHARMA/
IPCA LABS
 
P/E (TTM) x 19.3 51.7 37.3% View Chart
P/BV x 14.1 5.4 262.8% View Chart
Dividend Yield % 0.2 0.3 47.4%  

Financials

 SHUKRA PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHUKRA PHARMA
Mar-23
IPCA LABS
Mar-23
SHUKRA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs891,062 8.4%   
Low Rs11768 1.4%   
Sales per share (Unadj.) Rs53.7243.0 22.1%  
Earnings per share (Unadj.) Rs4.019.4 20.7%  
Cash flow per share (Unadj.) Rs5.729.7 19.2%  
Dividends per share (Unadj.) Rs0.504.00 12.5%  
Avg Dividend yield %1.00.4 229.1%  
Book value per share (Unadj.) Rs23.1230.3 10.0%  
Shares outstanding (eoy) m10.96253.70 4.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.93.8 24.7%   
Avg P/E ratio x12.447.2 26.3%  
P/CF ratio (eoy) x8.830.8 28.4%  
Price / Book Value ratio x2.24.0 54.4%  
Dividend payout %12.420.6 60.3%   
Avg Mkt Cap Rs m547232,120 0.2%   
No. of employees `000NANA-   
Total wages/salary Rs m4412,876 0.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m58861,642 1.0%  
Other income Rs m121,518 0.8%   
Total revenues Rs m60063,160 1.0%   
Gross profit Rs m549,033 0.6%  
Depreciation Rs m182,616 0.7%   
Interest Rs m3482 0.6%   
Profit before tax Rs m447,453 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m02,534 0.0%   
Profit after tax Rs m444,919 0.9%  
Gross profit margin %9.114.7 62.2%  
Effective tax rate %0.834.0 2.3%   
Net profit margin %7.58.0 93.9%  
BALANCE SHEET DATA
Current assets Rs m53151,893 1.0%   
Current liabilities Rs m42518,058 2.4%   
Net working cap to sales %18.054.9 32.7%  
Current ratio x1.22.9 43.4%  
Inventory Days Days051 0.0%  
Debtors Days Days1,8736 31,978.6%  
Net fixed assets Rs m21934,336 0.6%   
Share capital Rs m39254 15.4%   
"Free" reserves Rs m21458,167 0.4%   
Net worth Rs m25358,420 0.4%   
Long term debt Rs m386,518 0.6%   
Total assets Rs m75086,229 0.9%  
Interest coverage x16.816.5 102.1%   
Debt to equity ratio x0.10.1 133.5%  
Sales to assets ratio x0.80.7 109.8%   
Return on assets %6.36.3 99.8%  
Return on equity %17.48.4 206.9%  
Return on capital %16.212.2 133.0%  
Exports to sales %042.9 0.0%   
Imports to sales %013.3 0.0%   
Exports (fob) Rs mNA26,434 0.0%   
Imports (cif) Rs mNA8,178 0.0%   
Fx inflow Rs m026,434 0.0%   
Fx outflow Rs m08,178 0.0%   
Net fx Rs m018,257 0.0%   
CASH FLOW
From Operations Rs m328,058 0.4%  
From Investments Rs m-44-7,250 0.6%  
From Financial Activity Rs m495,072 1.0%  
Net Cashflow Rs m375,881 0.6%  

Share Holding

Indian Promoters % 51.0 46.3 110.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.1 44.8 0.2%  
FIIs % 0.0 10.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 49.0 53.7 91.3%  
Shareholders   10,963 82,809 13.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHUKRA PHARMA With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on RELISH PHARMA vs IPCA Labs

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

RELISH PHARMA vs IPCA Labs Share Price Performance

Period RELISH PHARMA IPCA Labs S&P BSE HEALTHCARE
1-Day -2.00% 3.35% 1.18%
1-Month 18.32% 4.27% -0.75%
1-Year 528.10% 56.49% 61.82%
3-Year CAGR 229.50% 9.46% 18.16%
5-Year CAGR 114.18% 20.88% 19.79%

* Compound Annual Growth Rate

Here are more details on the RELISH PHARMA share price and the IPCA Labs share price.

Moving on to shareholding structures...

The promoters of RELISH PHARMA hold a 51.0% stake in the company. In case of IPCA Labs the stake stands at 46.3%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of RELISH PHARMA and the shareholding pattern of IPCA Labs.

Finally, a word on dividends...

In the most recent financial year, RELISH PHARMA paid a dividend of Rs 0.5 per share. This amounted to a Dividend Payout ratio of 12.4%.

IPCA Labs paid Rs 4.0, and its dividend payout ratio stood at 20.6%.

You may visit here to review the dividend history of RELISH PHARMA, and the dividend history of IPCA Labs.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.